Patents by Inventor Valli De Re

Valli De Re has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Idiotypic vaccine
    Patent number: 8512703
    Abstract: The invention concerns the use of recombinant clonotypic immunoglobulins (Ig) as a vaccine in the treatment of HCV-related and non HCV-related lymphoproliferations, in particular the use of recombinant proteins with immunogenic properties derived from protein segments VK3-20 and VK3-15 of Ig light chains derived from patients with lymphoproliferations.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: August 20, 2013
    Assignee: Areta International S.R.L.
    Inventors: Riccardo Dolcetti, Massimo Guidoboni, Valli De Re, Daniela Gasparotto, Sonia Castiglioni, Maria Luisa Nolli
  • IDIOTYPIC VACCINE
    Publication number: 20100310586
    Abstract: The invention concerns the use of recombinant clonotypic immunoglobulins (Ig) as a vaccine in the treatment of HCV-related and non HCV-related lymphoproliferations, in particular the use of recombinant proteins with immunogenic properties derived from protein segments VK3-20 and VK3-15 of Ig light chains derived from patients with lymphoproliferations.
    Type: Application
    Filed: July 24, 2008
    Publication date: December 9, 2010
    Applicant: ARETA INTERNATIONAL S.r.l
    Inventors: Riccardo Dolcetti, Massimo Guidoboni, Valli De Re, Daniela Gasparotto, Sonia Castiglioni, Maria Luisa Nolli
  • Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
    Publication number: 20080248042
    Abstract: This invention disclosed a monoclonal antibody or a derivative thereof which is cross-reactive against the immunogenic sequence of an infective agent causing a B-cell expansion and IgG-Fc, said infective agent is selected from the group consisting of staphylococcus, HCV, HSV-1, HSV-2, varicella-zoster, CMV, and EBV. The monoclonal antibody is cross-reactive against helicase domain of HCV-NS3 and human IgG-Fc, in particular is cross-reactive against NS31246-1258 and IgG-Fc345-355. Hybridoma producing the antibody of is also provided. Methods for treating an infection, or for treating an autoimmune disease related to an infective agent, said agent causing B-cell expansion, type II mixed cryoglobulinemia, HCV-related neoplastic disease, non-Hodgkin lymphoma are disclosed.
    Type: Application
    Filed: April 5, 2007
    Publication date: October 9, 2008
    Applicant: IRCCS CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO,
    Inventors: Valli De Re, Maria Paola Simula, Laura Caggiari, Annunziala Gloghini